DK1532981T3 - Stabile öjendråber, der indeholder latanoprost som den aktive bestanddel - Google Patents

Stabile öjendråber, der indeholder latanoprost som den aktive bestanddel

Info

Publication number
DK1532981T3
DK1532981T3 DK03795230T DK03795230T DK1532981T3 DK 1532981 T3 DK1532981 T3 DK 1532981T3 DK 03795230 T DK03795230 T DK 03795230T DK 03795230 T DK03795230 T DK 03795230T DK 1532981 T3 DK1532981 T3 DK 1532981T3
Authority
DK
Denmark
Prior art keywords
active ingredient
eye drops
latanoprost
drops containing
containing latanoprost
Prior art date
Application number
DK03795230T
Other languages
Danish (da)
English (en)
Inventor
Hiroyuki Asada
Akio Kimura
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK1532981T3 publication Critical patent/DK1532981T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK03795230T 2002-08-23 2003-08-22 Stabile öjendråber, der indeholder latanoprost som den aktive bestanddel DK1532981T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002243955 2002-08-23
JP2002336242 2002-11-20
PCT/JP2003/010607 WO2004024164A1 (ja) 2002-08-23 2003-08-22 ラタノプロストを有効成分とする安定な点眼液

Publications (1)

Publication Number Publication Date
DK1532981T3 true DK1532981T3 (da) 2008-01-28

Family

ID=31996094

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03795230T DK1532981T3 (da) 2002-08-23 2003-08-22 Stabile öjendråber, der indeholder latanoprost som den aktive bestanddel

Country Status (12)

Country Link
US (2) US20050228048A1 (de)
EP (1) EP1532981B1 (de)
KR (2) KR101027454B1 (de)
CN (2) CN100591333C (de)
AT (1) ATE374031T1 (de)
AU (1) AU2003262268A1 (de)
CA (1) CA2496540C (de)
DE (1) DE60316574T2 (de)
DK (1) DK1532981T3 (de)
ES (1) ES2294361T3 (de)
PT (1) PT1532981E (de)
WO (1) WO2004024164A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2498233C (en) * 2002-09-09 2012-08-14 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
ATE412400T1 (de) 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
US8030349B2 (en) * 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
WO2007067208A1 (en) * 2005-12-09 2007-06-14 Teva Pharmaceutical Industries Ltd. Aqueous dispersions and solutions of difficult to dissolve compounds and methods of their preparation
EP1985298A1 (de) 2007-04-24 2008-10-29 Azad Pharma AG Prostaglandinhaltige Öl-in-Wasser-Emulsionen für das Auge
CN102014920B (zh) * 2008-04-23 2012-10-03 大塚制药株式会社 滴眼剂制剂及其应用
US10463677B2 (en) * 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
EP2228058A1 (de) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
EP2389939A1 (de) 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
CN110721260A (zh) * 2019-10-29 2020-01-24 深圳市瑞霖医药有限公司 一种新型拉坦前列素滴眼液

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU684115B2 (en) * 1993-12-27 1997-12-04 Mitsubishi Chemical Corporation Ophthalmic suspension containing diflupredonate
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AU7680096A (en) * 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
JP3480549B2 (ja) * 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
KR100508227B1 (ko) * 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
CN1146423C (zh) * 1998-07-14 2004-04-21 阿尔康实验室公司 前列腺素产品
JP2001081048A (ja) * 1999-09-10 2001-03-27 Wakamoto Pharmaceut Co Ltd 眼圧降下剤
JP4757970B2 (ja) * 1999-10-14 2011-08-24 久光製薬株式会社 点眼剤組成物
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
US20040097592A1 (en) * 2000-09-13 2004-05-20 Kenji Morishima Eye drops
CA2498233C (en) * 2002-09-09 2012-08-14 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient

Also Published As

Publication number Publication date
CA2496540A1 (en) 2004-03-25
CN100361661C (zh) 2008-01-16
EP1532981A4 (de) 2005-10-12
ES2294361T3 (es) 2008-04-01
PT1532981E (pt) 2007-12-12
DE60316574D1 (de) 2007-11-08
EP1532981B1 (de) 2007-09-26
US20050228048A1 (en) 2005-10-13
CN1684688A (zh) 2005-10-19
KR101027454B1 (ko) 2011-04-06
CA2496540C (en) 2011-01-25
AU2003262268A1 (en) 2004-04-30
KR20100132557A (ko) 2010-12-17
DE60316574T2 (de) 2008-07-03
KR20050038624A (ko) 2005-04-27
WO2004024164A1 (ja) 2004-03-25
CN101023927A (zh) 2007-08-29
EP1532981A1 (de) 2005-05-25
US20110118348A1 (en) 2011-05-19
CN100591333C (zh) 2010-02-24
ATE374031T1 (de) 2007-10-15

Similar Documents

Publication Publication Date Title
DK1532981T3 (da) Stabile öjendråber, der indeholder latanoprost som den aktive bestanddel
MXPA03011947A (es) Formulaciones de olopatidina para administracion topica.
BR0317421A (pt) Géis de fase única não-aquosa estável e formulações destes para liberação a partir de um dispositivo implantável
GT199900072A (es) Jarabe antihistaminico estabilizado.
DE60208494D1 (de) Herzfrequenzüberwachungsgerät
EP0642789A4 (de)
CY1108593T1 (el) Συμπυκνωμενο υδατικο διαλυμα αμβροξολης
DE60104872D1 (de) Stabilisierte ophthalmische wasserstoffperoxidlösung
NO20050612L (no) Pyrrolidinderivater som oksytocinantagonister
EP1930024A3 (de) G-CSF Lösungsformulierung mit Langzeitstabilität
DE50209545D1 (de) Flüssigkristallines medium
HUP0303255A2 (hu) Peszticid hatású 4"-helyettesített avermektin-sók, a vegyületeket tartalmazó készítmények és alkalmazásuk
CR9831A (es) Formulaciones de plaguicidas con riesgo de cristalizacion y procedimiento para su obtencion
DE69913116D1 (de) Orale flüssige lösung enthaltend das antidepressivum mirtazapine
NO20025081L (no) Stabilt flytende preparat
HRP20080544T3 (en) Benzothiazole formulations and use thereof
DK1692092T3 (da) Anvendelse af bis-aminer til forstærkning af den antimikrobielle aktivitet af vandige sammensætninger
RS24504A (en) Selective heribicides based on substituted thien-3-yl- sulfonylamino (thio)carbonyltriazolin (thi)ones and safeners
DE60226836D1 (de) Stabile Elektrolytlösungen enthaltend Taurolidin
DK534087A (da) Desinfektionsmiddel indeholdende en stabiliseret hydrogenperoxidoploesning til desinfektion af bloede kontaktlinser
ES2076838T3 (es) Nuevo derivado de la isoindolinona, su preparacion y las composiciones farmaceuticas que le contienen.
ATE333796T1 (de) Flüssige antimikrobielle zusammensetzungen
RS51119B (sr) Formulacije benzotijazola i njegova upotreba
WO2004005220A3 (fr) Procede de resolution asymetrique d'un racemique faisant intervenir 2,3:4,6-di-o-isopropyilidene-2-keto-l-gulonique
RU2006123317A (ru) Состав раствора эритропоэтина